EOS imaging Reports 46% Revenue Growth for the First Nine Months of 2012

Regulatory News:

EOS Imaging (NYSE Euronext, FR0011191766 – EOSI) (Paris:EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announces its revenue for the third quarter and first nine months of the financial year 2012.

• Quarterly change in revenue

• Third-quarter revenue: +86%

EOS imaging’s revenue for the third quarter of 2012 totaled €2.48 million, an increase of 86% compared with the same quarter of the previous year.

Equipment sales were up 99% at €2.21 million. Over the period, the Company sold 5 EOS® systems, compared with 3 systems in 2011. The average selling price of each system during the first nine months of 2012 was €439,000, compared with €392,000 in 2011.

• 9-month revenue: +46%

The Company recorded revenue of €4.81 million over the first nine months of 2012, an increase of 46% compared to the same period of 2011.

Equipment sales for the first nine months of 2012 were €4.19 million, or 87% of total revenue, up 48% compared to the same period in the previous year. This figure corresponds to the sale of 11 EOS® systems, compared with 7 over the same period of 2011. Sales of services, which primarily consist of maintenance contracts, grew by 33% to €0.62 million, and represented 13% of total revenue.

• 9-month revenue by geographical zone

Over the first nine months of the year, international sales totaled €4.0 million and accounted for 86% of total revenue. This figure corresponds to the sale of 9 EOS® systems, including 5 systems sold during the third quarter.

Marie Meynadier, CEO of EOS imaging, says: "This impressive quarter, with the sale of 5 EOS systems, shows that we are continuing our progress, particularly in the North American and Asia-Pacific markets. We also entered Scandinavia during the third quarter, a region that is particularly sensitive to reduction in medical irradiation. We will attend at the end of November the Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting, the leading international forum on medical imaging that brings together opinion leaders and decision makers from the top medical establishments.”

For further information about the Company or EOS®, the first full body, low dose 3D imaging system, please visit www.eos-imaging.com.

About EOS imaging:

The EOS imaging group designs, develops and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Group has obtained authorization to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EU). Thanks to an installed base of 51 sites and more than 250,000 imaging sessions, EOS® benefits from worldwide recognition and established credibility within the medical community. The Group currently employs 57 people, including an R&D team of 21 engineers, and recorded consolidated revenue of €6.94 million in 2011. The Group's head office is based in Paris, with a subsidiary in the United States in Cambridge (Massachusetts), as well as in Montreal (Canada) and Germany. For further information, please go to: www.eos-imaging.com

EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: 2012 annual revenue on 28 January 2013 (after market).